MaxCyte, Inc. (AIM:MXCT)

Market Cap	257.65M
Revenue (ttm)	30.85M
Net Income (ttm)	-32.79M
Shares Out	106.03M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,852
Average Volume	34,743
Open	240.66
Previous Close	243.00
Day's Range	240.66 - 240.66
52-Week Range	226.00 - 410.00
Beta	1.20
RSI	33.27
Earnings Date	Mar 11, 2025

About MaxCyte

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineerin...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1998
• Employees: 114
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: MXCT

Financial Performance

In 2024, MaxCyte's revenue was $38.63 million, a decrease of -6.44% compared to the previous year's $41.29 million. Losses were -$41.06 million, 8.26% more than in 2023.

Financial numbers in USD